Increasing

the odds

Giving everyone diagnosed with cancer, their best chance to become cancer free.

Increasing the odds

56%

Studies in upper gastrointestinal cancer have shown that up to 56% of patients¹ with early stage disease have previously undetected cancer cells in lymph nodes.

This can lead to inaccurate diagnosis and disease recurrence. Ferronova has developed a surgical oncology tracer system that aims to improve the treatment guidance and staging of complex cancers and help increase survival rates.

The gap

More than 40% of people will be diagnosed with cancer during their lifetime. Successful cancer treatment relies on accurate therapies to remove or treat lymph nodes at high risk of containing cancer. Current technologies and methods sometimes leave behind lymph nodes with cancer cells and are not able to reliably detect small tumours in removed lymph nodes.

Our solution

Our unique IP technology is a new-generation, polymer-coated magnetic nanoparticle.

This nanoparticle is detected on MRI for radiotherapy and surgical planning. It also drives a magnetically guided detection system designed to precisely identify sentinel lymph nodes, to assist surgeons and pathologists to more accurately stage solid tumours and locate and address micro-metastases that may otherwise go undetected.

The future of cancer

imaging and surgery

Generate a clear roadmap of the lymphatic system for precise surgical lymph node resection and radiation planning

Facilitate accurate identification of true sentinel nodes for pathology ultra-staging

Enable detection of micro-metastases that would otherwise be missed

Gastrointestinal cancers

The magnetic technology is well suited to complex cancers like colorectal and upper GI cancers, where resolution and the ability to locate sentinel lymph nodes close to the injection site are critical.

Our roadmap

May 2016

2020-2023

2024+

Ferronova Incorporated

First In-human and Feasibility Trials

Pivotal Trials

Our roadmap

May 2016

Ferronova Incorporated

2020-2023

First In-human and Feasibility Trials

2024+

Pivotal Trials

Clinical trials

Ferronova has completed a 15 patient first in-human trial and has multiple trials in progress.

1. Matsumoto, M., Natsugoe, S., Nakashima, S., Sakamoto, F., Okumura, H., Sakita, H., Baba, M., Takao, S. and Aikou, T., 2000. Clinical significance of lymph node micrometastasis of pN0 esophageal squamous cell carcinoma. Cancer letters, 153(1-2), pp.189-197